Aardvark Shares Exploratory PWS Data, Plans New Phase 3

Aardvark reported exploratory data from its terminated HERO and OLE trials in PWS and plans to meet the FDA on a new Phase 3 trial at a lower dose of ARD-101. The FDA lifted the ARD-101 clinical hold on Oct. 22, 2026.